In the fast-evolving field of drug discovery, innovative collaborations are often the key to unlocking new therapeutic avenues. Recently, SPT Labtech partnered with BellBrook Labs to enhance the process of screening VPS4B ATPase inhibitors, aimed at cancer treatment. This partnership exemplifies how automation and miniaturization can revolutionize complex life science workflows, making significant strides in oncology research.
The Heart of Automation
SPT Labtech emphasizes the importance of personalized collaboration with its clients. According to CEO Rob Walton, the company’s philosophy revolves around understanding the specific needs of customers to develop tailored automation solutions. Many clients possess clear objectives but may lack the expertise to implement effective automation strategies. This is where SPT Labtech’s extensive experience in positive displacement technology comes into play, enabling them to provide high precision and low-volume liquid dispensing capabilities.
A Groundbreaking Collaboration
The recent collaboration between SPT Labtech and BellBrook Labs was unveiled at the Society for Laboratory Automation and Screening (SLAS) annual meeting. Together, they developed a miniaturized, high-throughput cell-based assay specifically designed to discover and profile VPS4B ATPase inhibitors. VPS4B has gained recognition as a crucial therapeutic target due to its overexpression in certain tumors and its synthetic-lethal relationship with VPS4A, its paralog.
Innovative Assay Design
The newly developed assay integrates BellBrook Labs’ Transcreener® ADP2 fluorescence polarization assay with SPT Labtech’s dragonfly® system. The Transcreener assay enables direct detection of adenosine diphosphate (ADP), while the dragonfly system facilitates automated reagent dispensing. This powerful combination operates in both 384- and 1536-well formats and has already led to the identification of 13 novel VPS4B inhibitors, marking a significant achievement in the drug discovery process.
Reducing Barriers in Drug Discovery
Justin Brink, president of BellBrook Labs, heralded the assay as a transformative tool for biotechnology and pharmaceutical teams targeting complex ATPases. This new approach has lowered barriers to VPS4B screening, enabling researchers to significantly reduce reagent consumption while maintaining the high Z’ values and data sensitivity essential for accurate hit identification. This advancement could accelerate the pace of drug discovery in oncology.
The Landscape of Automation
SPT Labtech’s partnership with BellBrook Labs aligns with the company’s broader focus on genomic applications. Walton noted that many of their collaborations center around DNA and RNA sequencing and library preparation. For instance, earlier this year, they introduced validated automated workflows for Twist Bioscience’s next-generation sequencing library preparation kits, showcasing their commitment to enhancing genomic research capabilities.
The Automation Challenge
Automation projects, such as the one with BellBrook Labs, can take anywhere from one to three months to complete, depending on the application’s complexity. Walton highlighted the challenges presented by the differences between manual and automated processes, particularly in terms of volume requirements. Successful automation must replicate manual processes with the same level of accuracy and reliability, necessitating extensive experimentation and refinement of protocols.
Enhancements in User Experience
In addition to their collaborative projects, SPT Labtech is also focused on enhancing its three core liquid handling platforms. Recent upgrades to the mosquito and dragonfly systems aim to improve user experience and increase “walkaway” capabilities. These updates include significant enhancements to pipetting functionality and user interfaces, making the systems more intuitive and easier to operate.
Global Expansion and Demand
As SPT Labtech continues to innovate, the company is also expanding its production facilities and workforce in key global markets, including China and India. Walton noted that even in highly competitive markets, SPT Labtech’s unique capabilities are attracting substantial demand. This growth illustrates the company’s commitment to addressing the needs of researchers worldwide.
In conclusion, the collaboration between SPT Labtech and BellBrook Labs represents a significant advancement in the screening of VPS4B ATPase inhibitors for cancer drug discovery. Through innovative automation and tailored solutions, these companies are paving the way for more efficient and effective research in oncology. As technology continues to evolve, partnerships like this will be crucial in the ongoing quest to develop new treatments and improve patient outcomes.
- Innovative automation is transforming drug discovery processes.
- The collaboration successfully identifies multiple novel VPS4B inhibitors.
- Enhanced user experiences in liquid handling systems are a priority.
- Global expansion reflects rising demand for advanced research capabilities.
Read more → www.genengnews.com